SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Clinical trial NCT06743126 · RECRUITING

Trial details

NCT number: NCT06743126
Sponsor: Immatics US, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Melanoma, Cutaneous Malignant

Start date: 2025-01-14
Primary completion: 2028-01-01
Enrollment: 360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.